Even modern kidney-protective drugs couldn't offset the harm
For decades, dihydropyridine calcium-channel blockers have been a trusted tool in managing blood pressure among patients navigating the compounding burdens of type 2 diabetes and kidney disease. Now, a large observational study presented at the ERA Congress suggests these familiar medications may quietly accelerate the very harm they are meant to prevent — even alongside the most advanced kidney-protective therapies available. The finding does not yet carry the weight of proof, but it carries the weight of consequence: millions of patients, and the physicians who care for them, may need to reconsider what 'standard of care' truly means.
- A study of more than 31,000 diabetic patients found that those taking DCCBs faced a 33% higher risk of serious kidney decline — even when already protected by the most modern therapies.
- The suspected mechanism is unsettling: these drugs may selectively relax the wrong blood vessels in the kidney, raising internal pressure in filtering units already pushed to their limits by diabetes.
- The hope that SGLT2 inhibitors would neutralize any DCCB-related harm was tested — and did not hold, leaving a gap in the logic that has guided prescribing for years.
- Because the study was observational, causation remains unproven, but the scale of DCCB use means even a modest real risk could translate to thousands of preventable kidney failures.
- Researchers are urgently calling for randomized controlled trials to settle the question and chart safer paths for a population that cannot afford to wait long for answers.
A study presented at the 63rd ERA Congress has cast an unexpected shadow over one of the most commonly prescribed blood pressure medications for people with type 2 diabetes and kidney disease. Dihydropyridine calcium-channel blockers — DCCBs — have long served as a reliable second-line option in this population. The new research suggests they may be accelerating kidney damage rather than protecting against it.
Diabetic kidney disease is a slow erosion: years of high blood sugar wear down the kidneys' delicate filtering structures, eventually pushing patients toward dialysis or transplant. Blood pressure control is a cornerstone of slowing that progression. In recent years, two drug classes — RAS inhibitors and SGLT2 inhibitors — have reshaped the standard of care, offering meaningful protection against end-stage disease. The study asked what happens when DCCBs are added on top of these modern therapies.
Among more than 31,000 adults already receiving both RAS and SGLT2 inhibitors, roughly 39 percent were also taking DCCBs. After a median follow-up of 3.5 years, those patients showed a 33 percent higher risk of major adverse kidney events — steep functional decline or progression to end-stage disease — compared to those on alternative blood pressure treatments. Lead author Dr. Timna Agur noted that the team had hoped SGLT2 inhibitors might offset any DCCB-related harm. They did not.
The suspected mechanism points to how DCCBs interact with kidney blood vessels. By preferentially relaxing the vessels that carry blood into the kidney's filtering units — without equally relaxing those carrying blood out — the drugs may inadvertently raise pressure within structures already strained by diabetes. It is, in effect, the physiological opposite of the intended goal.
The study was observational and cannot establish direct causation. Yet the sheer number of patients taking DCCBs globally means that even a modest real risk could produce thousands of additional kidney failures. The researchers are calling for randomized controlled trials to confirm the findings. In the meantime, the study poses a quiet but pressing question for clinicians: in an era of expanding therapeutic options, which long-trusted treatments deserve a second look?
A study presented at the 63rd ERA Congress has raised an unexpected concern about a class of blood pressure medications that doctors have long relied on for patients with type 2 diabetes and kidney disease. Dihydropyridine calcium-channel blockers, or DCCBs, are among the most commonly prescribed second-line treatments for controlling blood pressure in this population. But new research suggests they may be doing more harm than good—even when patients are already taking the most modern kidney-protective drugs available.
Diabetic kidney disease develops when years of high blood sugar gradually damage the delicate blood vessels inside the kidneys, eroding their ability to filter waste. It is one of the leading causes of kidney failure worldwide. Blood pressure control is central to slowing this damage, which is why doctors layer medications carefully. In recent years, two classes of drugs have transformed the standard of care: RAS inhibitors, which reduce pressure both in the bloodstream and within the kidney's filtering units, and SGLT2 inhibitors, originally developed for diabetes but now recognized as powerful kidney protectors that can prevent progression to end-stage disease.
The new study examined data from more than 31,000 adults with type 2 diabetes between 2016 and 2021. All of them were already receiving both RAS inhibitors and SGLT2 inhibitors—the modern standard. Among these patients, about 39 percent were also taking DCCBs, while the remaining 61 percent received other blood pressure medications. Researchers followed them for a median of 3.5 years and looked for major adverse kidney events: either a steep decline in kidney function (a drop of 40 percent or more in the standard measure of filtration) or progression to end-stage kidney disease requiring dialysis or transplant.
The findings were striking. After accounting for differences in baseline health and demographics, patients taking DCCBs had a 33 percent higher risk of these major adverse events compared to those on alternative blood pressure treatments. The increased risk persisted even though these patients were already on the kidney-protective therapies that have become the foundation of modern diabetic kidney disease care. Dr. Timna Agur, the study's lead author, noted that researchers had initially hoped the protective effects of SGLT2 inhibitors might offset any potential harm from DCCBs. That did not happen.
The mechanism behind the finding may lie in how DCCBs work. These drugs relax blood vessels by blocking calcium channels, which lowers blood pressure overall. But in the kidney, the effect may be uneven. In diabetic kidney disease, the filtering units are already under excessive strain from high blood sugar and high pressure. DCCBs may preferentially relax the vessels carrying blood into these units without having the same effect on the vessels carrying blood out. The result could be increased pressure within the filtering structures themselves—the opposite of what doctors want.
Agur emphasized that the study was observational, meaning it cannot prove that DCCBs directly cause the worse outcomes. Patients taking these drugs may have differed in unmeasured ways from those on other medications. But the sheer scale of DCCB use in this population makes the findings clinically significant. Millions of people with type 2 diabetes and kidney disease take these medications. Even a modest increase in risk, if real, could translate to thousands of additional cases of kidney failure.
The researchers are calling for randomized controlled trials to confirm the observation and to identify the safest blood pressure treatment strategies for patients with diabetic kidney disease. Until then, the study serves as a reminder that even widely accepted treatments deserve scrutiny, especially when newer, more targeted therapies have changed the landscape of care. For patients and doctors alike, it raises an uncomfortable question: what other standard practices might need reconsideration in light of modern medicine's expanding toolkit?
Notable Quotes
Our findings raise important questions about whether these medications are always the best option for patients already receiving modern kidney-protective therapies.— Dr. Timna Agur, lead author
We initially thought the kidney-protective effects of SGLT2 inhibitors might counterbalance the potential harms associated with DCCBs. However, the increased risk of kidney disease progression appeared to persist even in this group.— Dr. Timna Agur
The Hearth Conversation Another angle on the story
Why would a blood pressure drug that's been used for years suddenly look dangerous?
It's not that it became dangerous. It's that we now have better kidney-protective drugs—SGLT2 inhibitors and RAS inhibitors—that change the equation. When those weren't available, DCCBs were the best option. Now that we have them, the comparison looks different.
So the drug itself hasn't changed, but the context has?
Exactly. And the mechanism matters too. DCCBs relax blood vessels, but they may do it unevenly in the kidney. They might ease pressure on the way in but not on the way out, which in a kidney already under strain from diabetes could actually make things worse.
If this is observational data, why should anyone change their treatment?
Because the signal is large—33 percent higher risk—and because the population is enormous. Even if only some of that risk is real, the absolute number of people affected could be substantial. It's not a reason to panic, but it's a reason to study it carefully and maybe reconsider prescribing patterns.
What happens to someone already taking one of these drugs?
They shouldn't stop suddenly. That would be dangerous. But they should talk to their doctor about whether an alternative might be safer, especially if they're already on modern kidney-protective therapies. The study doesn't say DCCBs are poison—it says they may not be the best choice in this specific context.
How long until we know if this is real?
Randomized controlled trials would take years. In the meantime, doctors will likely become more cautious about prescribing DCCBs to diabetic patients with kidney disease, and that's probably appropriate. The burden of proof shifts when you have safer alternatives available.